title: Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
abstract: Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S. primary care settings would expand access to treatment for this condition. Models for integrating MAT into primary care vary in structure. This article summarizes findings of a technical report for the Agency for Healthcare Research and Quality describing MAT models of care for OUD, based on a literature review and interviews with key informants in the field. The report describes 12 representative models of care for integrating MAT into primary care settings that could be considered for adaptation across diverse health care settings. Common components of existing care models include pharmacotherapy with buprenorphine or naltrexone, provider and community education, coordination and integration of OUD treatment with other medical and psychological needs, and psychosocial services and interventions. Models vary in how each component is implemented. Decisions about adopting MAT models of care should be individualized to address the unique milieu of each implementation setting.
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: P Todd
authors.initials: PT
authors.lastname: Korthuis
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Dennis
authors.initials: D
authors.lastname: McCarty
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Melissa
authors.initials: M
authors.lastname: Weimer
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Christina
authors.initials: C
authors.lastname: Bougatsos
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Ian
authors.initials: I
authors.lastname: Blazina
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Bernadette
authors.initials: B
authors.lastname: Zakher
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Sara
authors.initials: S
authors.lastname: Grusing
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Beth
authors.initials: B
authors.lastname: Devine
authors.affiliation: From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington.
authors.forename: Roger
authors.initials: R
authors.lastname: Chou
mesh_terms: D002047:Buprenorphine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004502:Education, Medical, Continuing; D006266:Health Education; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment; D009293:Opioid-Related Disorders / Q000150:complications / Q000188:drug therapy*; D011320:Primary Health Care / Q000458:organization & administration*; D011613:Psychotherapy
chemical_list: D009292:Narcotic Antagonists; D002047:Buprenorphine; D009271:Naltrexone